On January 10, Gelonghui reported that Beijing Bayi Space Lcd Technology Co., Ltd. (688181.SH) recently stated during an institutional investor research meeting that the company's pharmaceutical Business is relatively stable, with customized production based on customer needs; as a liquid crystal company, the biggest advantage is its strong organic synthesis capability. The company develops hundreds of new compound structures every year, reflecting the team's strong R&D capabilities, which is also evident in the pharmaceutical sector.

Considering the company has a certain reserve of synthesis technology in the pharmaceutical field, with diversified market customers, diverse applications, and the ability to easily scale up, it can contribute revenue and profit to the company more effectively.

The pharmaceutical team is an independent and relatively mature team, having achieved tens of millions in revenue in 2024. It is expected to achieve hundreds of millions in revenue for the entire year of 2025.

In addition, the company has obtained the pesticide production license and will continue to prepare for Active Pharmaceutical Ingredient certification, which will help with future product upgrades and gross profit enhancement.